When Paul Sufka, MD, a rheumatologist with HealthPartners Medical Group and Regions Hospital in St. Paul, Minn., wants to connect with his colleagues or keep abreast of the latest rheumatology journal articles, he turns to Twitter. Dr. Sufka is one of many rheumatologists who have found effective ways to incorporate social media into their medical…
Experts Discuss Proposed Giant Cell Arteritis Risk Tool
A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…
New Study Examines Treatment Options for Incomplete Lupus Erythematous
A recent study explored medical concerns for patients who have lupus markers, but fall short of meeting enough criteria for official disease classification. Investigators at the Oklahoma Medical Research Foundation conducted a large study to explore current treatments of patients with incomplete lupus erythematous (ILE) and to compare antibody characteristics to healthy people and patients…
New Study Examines the Physical Activity & Joint Symptom Risk
If you’re a middle-aged woman who makes a New Year’s resolution to work out regularly and you keep that promise for only six months, don’t think that will go far in protecting your joints. Researchers in Australia have homed in on the details of the sustained physical activity required to reduce the risk of joint…
The 75-Year History of PANLAR
The first organization dedicated to fighting rheumatic disease was the International League Against Rheumatism (ILAR), founded in 1928 under the guidance of a Dutch national, Dr. Jan van Breemen. Interest in rheumatology quickly spread throughout the American continent, and the American Association for the Study and Control of Rheumatism met in Cleveland, for what they…
How & Why Attending Physicians Should Teach in Patient Rooms
No matter where you practice, rheumatology clinics are extremely busy. And in that hustle and bustle we find an uncomfortable jostling of priorities between delivering optimal care for as many patients as possible and upholding education for teachers and learners at all levels. Because salary usually comes from seeing more and more patients, teaching is…
Kussmaul, Meier & Polyarteritis Nodosa
In 1866, Adolf Kussmaul, an internist, and Rudolf Maier, a pathologist, published the classic characterization of what eventually became known as polyarteritis nodosa.1 It was the first scientific clinical characterization of a noninfectious vasculitis. As such, it became a paradigmatic point of contrast to other types of vasculitides that were later described. Their description also…
Patients Lose When Insurance Company Forces Drug Switch
This past June, a 64-year-old man with a history of psoriatic arthritis and severe arthritis appeared at our clinic for his regular follow-up with concerns about a letter from his insurance company. The letter stated the company wouldn’t pay for the patient’s secukinumab (i.e., Cosentyx) prescription anymore and suggested he take ixekizumab (i.e., Taltz) instead,…
Septic or Lyme Hip Arthritis? Rapid Lyme Diagnostics Could Avoid Unnecessary Treatment
NEW YORK (Reuters Health)—In Lyme-endemic areas, synovial fluid white blood cell (WBC) count isn’t very helpful in distinguishing septic from Lyme arthritis of the hip, a new study suggests. Use of newer-generation Lyme disease diagnostics are necessary to avoid the “under- and overdiagnosis of Lyme arthritis at the time that initial management decisions must be…
FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib
(Reuters)—An experimental rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp. poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff says, the latest setback to a treatment regulators declined to approve last year. New data provided by the companies in a resubmission of their marketing…
- « Previous Page
- 1
- …
- 304
- 305
- 306
- 307
- 308
- …
- 776
- Next Page »